166 related articles for article (PubMed ID: 25831762)
1. [Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
Nishida T; Tsukazaki K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():250-5. PubMed ID: 25831762
[No Abstract] [Full Text] [Related]
2. Management of the new patient with CML in chronic phase.
Marin D
Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
[TBL] [Abstract][Full Text] [Related]
3. The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia.
Togasaki-Yoshimoto E; Shono K; Onoda M; Yokota A
Leuk Lymphoma; 2014 Feb; 55(2):453-6. PubMed ID: 23697842
[No Abstract] [Full Text] [Related]
4. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Schiffer CA
N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
[No Abstract] [Full Text] [Related]
5. [Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
Miura M; Takahashi N
Rinsho Ketsueki; 2013 Oct; 54(10):1720-9. PubMed ID: 24064822
[No Abstract] [Full Text] [Related]
6. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Beyer C; Distler JH; Distler O
Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia: advances in diagnosis and management.
Noronha S; Sawyer S
JAAPA; 2013 Feb; 26(2):26-9. PubMed ID: 23409382
[No Abstract] [Full Text] [Related]
8. High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.
Martz J; Jain S; Vahdat LT; Qin L; Mosquera JM; Antonescu CR; Popa EC
J Clin Oncol; 2013 Apr; 31(11):e181-5. PubMed ID: 23439757
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib.
Lindauer M; Hochhaus A
Recent Results Cancer Res; 2010; 184():83-102. PubMed ID: 20072833
[TBL] [Abstract][Full Text] [Related]
11. Oral BMS-354825 rescues Gleevec-resistant CML.
Cancer Biol Ther; 2004 Aug; 3(8):700. PubMed ID: 15751154
[No Abstract] [Full Text] [Related]
12. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
Gallipoli P; Stobo J; Heaney N; Nicolini FE; Clark R; Wilson G; Tighe J; McLintock L; Hughes T; Michor F; Paul J; Drummond M; Holyoake TL
Br J Haematol; 2013 Dec; 163(5):674-6. PubMed ID: 24032404
[No Abstract] [Full Text] [Related]
14. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
15. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
17. Drugs offer new hope for patients with CML who are resistant to imatinib.
Oestreicher P
ONS Connect; 2007 Jul; 22(7):20-1. PubMed ID: 17694781
[No Abstract] [Full Text] [Related]
18. Second-generation BCR-ABL kinase inhibitors in CML.
Akard LP
N Engl J Med; 2010 Oct; 363(17):1672-3; author reply 1673-5. PubMed ID: 20973144
[No Abstract] [Full Text] [Related]
19. Targeted drugs in chronic myeloid leukemia.
Gora-Tybor J; Robak T
Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Wei G; Rafiyath S; Liu D
J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]